MX2007011672A - Nuevos derivados de tiofeno como agonistas del receptor de esfingosina-1-fosfato-1. - Google Patents

Nuevos derivados de tiofeno como agonistas del receptor de esfingosina-1-fosfato-1.

Info

Publication number: MX2007011672A
Authority: MX; Mexico
Prior art keywords: carboxylic acid; pyrrolidin; propoxy; hydroxy; alkyl
Prior art date: 2005-03-23

Application number

MX2007011672A

Other languages

English (en)

Spanish (es)

Inventor

Thomas Weller

Jorg Velker

Boris Mathys

Claus Mueller

Oliver Nayler

Martin Bolli

David Lehmann

Original Assignee

Actelion Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-03-23

Filing date

2006-03-20

Publication date

2007-11-15

2006-03-20 Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd

2007-11-15 Publication of MX2007011672A publication Critical patent/MX2007011672A/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Oncology (AREA)
Neurosurgery (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Transplantation (AREA)
Ophthalmology & Optometry (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Otolaryngology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

MX2007011672A 2005-03-23 2006-03-20 Nuevos derivados de tiofeno como agonistas del receptor de esfingosina-1-fosfato-1. MX2007011672A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP2005003070		2005-03-23
PCT/IB2006/050850 WO2006100633A1 (en)	2005-03-23	2006-03-20	NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-l-PHOSPHATE-1 RECEPTOR AGONISTS

Publications (1)

Publication Number	Publication Date
MX2007011672A true MX2007011672A (es)	2007-11-15

Family

ID=36699202

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MX2007011672A MX2007011672A (es)	2005-03-23	2006-03-20	Nuevos derivados de tiofeno como agonistas del receptor de esfingosina-1-fosfato-1.

Country Status (25)

Country	Link
US (1)	US7605269B2 (no)
EP (1)	EP1863474B1 (no)
JP (1)	JP5072825B2 (no)
KR (1)	KR20070116645A (no)
CN (1)	CN101146529B (no)
AR (1)	AR055751A1 (no)
AT (1)	ATE413874T1 (no)
AU (1)	AU2006226020A1 (no)
BR (1)	BRPI0609668A2 (no)
CA (1)	CA2602475C (no)
CY (1)	CY1108750T1 (no)
DE (1)	DE602006003642D1 (no)
DK (1)	DK1863474T3 (no)
ES (1)	ES2316062T3 (no)
IL (1)	IL186150A0 (no)
MX (1)	MX2007011672A (no)
NO (1)	NO20075298L (no)
NZ (1)	NZ562561A (no)
PL (1)	PL1863474T3 (no)
PT (1)	PT1863474E (no)
RU (1)	RU2404178C2 (no)
SI (1)	SI1863474T1 (no)
TW (1)	TW200700406A (no)
WO (1)	WO2006100633A1 (no)
ZA (1)	ZA200709087B (no)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4678139B2 (ja) *	2004-05-10	2011-04-27	トヨタ自動車株式会社	自動車の暖房制御システム
WO2006010379A1 (en) *	2004-07-29	2006-02-02	Actelion Pharmaceuticals Ltd.	Novel thiophene derivatives as immunosuppressive agents
CA2602475C (en)	2005-03-23	2014-11-04	Actelion Pharmaceuticals Ltd	Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists
BRPI0609515A8 (pt)	2005-03-23	2017-12-26	Actelion Pharmaceuticals Ltd	Composto, composição farmacêutica, e, uso de um composto
BRPI0609665A2 (pt) *	2005-03-23	2010-04-20	Actelion Pharmaceuticals Ltd	composto, composição farmacêutica, e, uso de um composto
CN101203503B (zh) *	2005-06-24	2011-12-28	埃科特莱茵药品有限公司	新颖噻吩衍生物
AR057894A1 (es) *	2005-11-23	2007-12-26	Actelion Pharmaceuticals Ltd	Derivados de tiofeno
TWI404706B (zh) *	2006-01-11	2013-08-11	Actelion Pharmaceuticals Ltd	新穎噻吩衍生物
KR20080092385A (ko) *	2006-01-24	2008-10-15	액테리온 파마슈티칼 리미티드	신규한 피리딘 유도체
MX356221B (es) *	2006-04-03	2018-05-18	Astellas Pharma Inc	Heterocompuesto.
AR061841A1 (es)	2006-09-07	2008-09-24	Actelion Pharmaceuticals Ltd	Derivados de tiofen-oxadiazoles, agonistas del receptor s1p1/edg1, composiciones farmaceuticas que los contienen y usos como agentes inmunomoduladores.
KR101470659B1 (ko)	2006-09-07	2014-12-08	액테리온 파마슈티칼 리미티드	면역조절제로서 피리딘-4-일 유도체
ES2400163T3 (es)	2006-09-08	2013-04-08	Actelion Pharmaceuticals Ltd.	Derivados de piridil-3-ilo como agentes de inmunomodulación
JO2701B1 (en)	2006-12-21	2013-03-03	جلاكسو جروب ليميتد	Vehicles
EP2125797B1 (en) *	2007-03-16	2014-01-15	Actelion Pharmaceuticals Ltd.	Amino- pyridine derivatives as s1p1 /edg1 receptor agonists
EA016443B1 (ru) *	2007-04-19	2012-05-30	Глэксо Груп Лимитед	Оксадиазолзамещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (s1p)
WO2009074950A2 (en) *	2007-12-10	2009-06-18	Actelion Pharmaceuticals Ltd	Thiophene derivatives as agonists of s1p1/edg1
PE20091339A1 (es)	2007-12-21	2009-09-26	Glaxo Group Ltd	Derivados de oxadiazol con actividad sobre receptores s1p1
GB0725101D0 (en)	2007-12-21	2008-01-30	Glaxo Group Ltd	Compounds
JP5411877B2 (ja) *	2008-03-06	2014-02-12	アクテリオンファーマシューティカルズリミテッド	ピリジン化合物
KR101615779B1 (ko) *	2008-03-07	2016-04-26	액테리온 파마슈티칼 리미티드	면역조절제로서 피리딘-2-일 유도체
PL2278960T5 (pl)	2008-03-17	2020-06-29	Actelion Pharmaceuticals Ltd.	Schemat dawkowania dla selektywnego agonisty receptora sip1
GB0807910D0 (en) *	2008-04-30	2008-06-04	Glaxo Group Ltd	Compounds
EP2297139A1 (en) *	2008-06-20	2011-03-23	Glaxo Group Limited	Compounds
KR20190004843A (ko)	2008-07-23	2019-01-14	아레나 파마슈티칼스, 인크.	자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[ｂ]인돌-3-일)아세트산 유도체
US8415484B2 (en)	2008-08-27	2013-04-09	Arena Pharmaceuticals, Inc.	Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
CN102361869A (zh)	2009-01-23	2012-02-22	百时美施贵宝公司	在治疗自身免疫性疾病和炎性疾病中作为s1p激动剂的取代的噁二唑衍生物
US8389509B2 (en)	2009-01-23	2013-03-05	Bristol-Myers Squibb Company	Substituted pyrazole compounds
JP2012515787A (ja)	2009-01-23	2012-07-12	ブリストル−マイヤーズスクイブカンパニー	自己免疫疾患および炎症性疾患の処置におけるｓ１ｐアゴニストとしての置換オキサジアゾール誘導体
WO2010117662A1 (en) *	2009-03-30	2010-10-14	Exelixis, Inc.	Modulators of s1p and methods of making and using
DE102009002514A1 (de)	2009-04-21	2010-10-28	Evonik Degussa Gmbh	Verfahren zur Herstellung von substituierten 1,4-Chinonmethiden
GB0910674D0 (en)	2009-06-19	2009-08-05	Glaxo Group Ltd	Novel compounds
DK2454255T3 (da)	2009-07-16	2013-12-16	Actelion Pharmaceuticals Ltd	Pyridin-4-ylderivater som s1p1/edg1-agonister
US8399451B2 (en)	2009-08-07	2013-03-19	Bristol-Myers Squibb Company	Heterocyclic compounds
AU2010319879A1 (en)	2009-10-29	2012-06-14	Bristol-Myers Squibb Company	Tricyclic heterocyclic compounds
WO2011094008A1 (en)	2010-01-27	2011-08-04	Arena Pharmaceuticals, Inc.	Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CN102884064B (zh)	2010-03-03	2016-01-13	艾尼纳制药公司	制备s1p1受体调节剂及其晶体形式的方法
JP5735634B2 (ja)	2010-04-23	2015-06-17	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	スフィンゴシン−１−リン酸受容体１アゴニストとしての４−（５−イソオキサゾリルまたは５−ピラゾリル−１，２，４−オキサジアゾール−３−イル）−マンデル酸アミド化合物
WO2012012477A1 (en)	2010-07-20	2012-01-26	Bristol-Myers Squibb Company	Substituted 3-phenyl-1,2,4-oxadiazole compounds
JP5869579B2 (ja)	2010-09-24	2016-02-24	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	置換オキサジアゾール化合物およびそれらのｓ１ｐ１アゴニストとしての使用
US8629282B2 (en)	2010-11-03	2014-01-14	Bristol-Myers Squibb Company	Heterocyclic compounds as S1P1 agonists for the treatment of autoimmune and vascular diseases
US9133179B2 (en)	2011-01-19	2015-09-15	Actelion Pharmaceuticals Ltd.	2-methoxy-pyridin-4-yl-derivatives
HRP20200883T1 (hr)	2012-08-17	2020-09-04	Actelion Pharmaceuticals Ltd.	Postupak za pripremanje (2z,5z)-5-(3-kloro-4-((r)-2,3-dihidroksipropoksi)benziliden)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona i međuproizvodi koji se koriste u navedenom postupku
UY35338A (es)	2013-02-21	2014-08-29	Bristol Myers Squibb Company Una Corporación Del Estado De Delaware	Compuestos bicíclicos moduladores de la actividad de s1p1 y composiciones farmacéuticas que los contienen
TWI689487B (zh)	2014-08-20	2020-04-01	美商必治妥美雅史谷比公司	經取代雙環化合物
SI3242666T1 (sl)	2015-01-06	2025-03-31	Arena Pharmaceuticals, Inc.	Spojina za uporabo pri zdravljenju stanj, povezanih z receptorjem s1p1
AU2015316719A1 (en)	2015-02-03	2017-09-07	Active Biotech Ab	Imidazo[2,1-b]thiazole and 5,6-dihydroimidazo[2,1-b]thiazole derivatives useful as S100-inhibitors
MA42107B1 (fr)	2015-05-20	2020-02-28	Idorsia Pharmaceuticals Ltd	Forme cristalline du composé (s)-3-{4-[5-(2-cyclopentyl-6-méthoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-éthyl-6-méthyl-phénoxy}-propane-1,2-diol
US10111841B2 (en)	2015-06-19	2018-10-30	University Of South Florida	Stabilization of alcohol intoxication-induced cardiovascular instability
KR102603199B1 (ko)	2015-06-22	2023-11-16	아레나 파마슈티칼스, 인크.	Ｓ1ｐ1 수용체-관련 장애에서의 사용을 위한 (ｒ)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[ｂ]인돌-3-일)아세트산 (화합물 1)의 결정성 ｌ-아르기닌 염
WO2017004608A1 (en) *	2015-07-02	2017-01-05	Exelixis, Inc.	Oxadiazole modulators of s1p methods of making and using
JP7029445B2 (ja)	2016-09-02	2022-03-03	ブリストル－マイヤーズスクイブカンパニー	置換された三環式ヘテロ環化合物
CN110520124A (zh)	2017-02-16	2019-11-29	艾尼纳制药公司	用于治疗原发性胆汁性胆管炎的化合物和方法
CA3053416A1 (en)	2017-02-16	2018-08-23	Arena Pharmaceuticals, Inc.	Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
US11046646B2 (en)	2017-08-09	2021-06-29	Bristol-Myers Squibb Company	Alkylphenyl compounds
WO2019032631A1 (en)	2017-08-09	2019-02-14	Bristol-Myers Squibb Company	OXIME ETHER COMPOUNDS
MA52778A (fr)	2018-06-06	2021-04-21	Arena Pharm Inc	Méthodes de traitement de troubles associés au récepteur s1p1
CN119751336A (zh)	2018-09-06	2025-04-04	艾尼纳制药公司	可用于治疗自身免疫性病症和炎性病症的化合物
US11014897B1 (en)	2018-10-16	2021-05-25	Celgene Corporation	Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof
US11013723B1 (en)	2018-10-16	2021-05-25	Celgene Corporation	Solid forms of a thiazolidinone compound, compositions and methods of use thereof
US11186556B1 (en)	2018-10-16	2021-11-30	Celgene Corporation	Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
US11014940B1 (en)	2018-10-16	2021-05-25	Celgene Corporation	Thiazolidinone and oxazolidinone compounds and formulations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU7686891A (en)	1990-04-05	1991-10-30	American National Red Cross, The	A protein family related to immediate-early protein expressed by human endothelial cells during differentiation
US5478847A (en) *	1994-03-02	1995-12-26	Eli Lilly And Company	Methods of use for inhibiting bone loss and lowering serum cholesterol
EP1070080A4 (en)	1998-03-09	2004-12-29	Smithkline Beecham Corp	HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND THEIR APPLICATIONS
GB9808665D0 (en) *	1998-04-23	1998-06-24	Merck Sharp & Dohme	Therapeutic compounds
CA2472713C (en)	2002-01-18	2011-07-19	Merck & Co., Inc.	N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists
US7199142B2 (en)	2002-06-17	2007-04-03	Merck & Co., Inc.	1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists
AU2003279915A1 (en)	2002-10-15	2004-05-04	Merck And Co., Inc.	Process for making azetidine-3-carboxylic acid
JP2006528980A (ja) *	2003-05-15	2006-12-28	メルク　エンド　カムパニー　インコーポレーテッド	Ｓ１ｐ受容体作働薬としての３−（２−アミノ−１−アザシクロ）−５−アリール−１，２，４−オキサジアゾール類
WO2006010379A1 (en) *	2004-07-29	2006-02-02	Actelion Pharmaceuticals Ltd.	Novel thiophene derivatives as immunosuppressive agents
CA2581501C (en)	2004-09-27	2013-03-26	Avon Protection Systems, Inc.	Respirator exhalation unit
BRPI0609515A8 (pt)	2005-03-23	2017-12-26	Actelion Pharmaceuticals Ltd	Composto, composição farmacêutica, e, uso de um composto
BRPI0609665A2 (pt)	2005-03-23	2010-04-20	Actelion Pharmaceuticals Ltd	composto, composição farmacêutica, e, uso de um composto
CA2602475C (en)	2005-03-23	2014-11-04	Actelion Pharmaceuticals Ltd	Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists
AR057894A1 (es)	2005-11-23	2007-12-26	Actelion Pharmaceuticals Ltd	Derivados de tiofeno
KR20080092385A (ko)	2006-01-24	2008-10-15	액테리온 파마슈티칼 리미티드	신규한 피리딘 유도체

2006
- 2006-03-20 CA CA2602475A patent/CA2602475C/en not_active Expired - Fee Related
- 2006-03-20 DK DK06727683T patent/DK1863474T3/da active
- 2006-03-20 MX MX2007011672A patent/MX2007011672A/es active IP Right Grant
- 2006-03-20 NZ NZ562561A patent/NZ562561A/en not_active IP Right Cessation
- 2006-03-20 KR KR1020077024345A patent/KR20070116645A/ko not_active Ceased
- 2006-03-20 AU AU2006226020A patent/AU2006226020A1/en not_active Abandoned
- 2006-03-20 RU RU2007138869/04A patent/RU2404178C2/ru not_active IP Right Cessation
- 2006-03-20 AT AT06727683T patent/ATE413874T1/de active
- 2006-03-20 DE DE602006003642T patent/DE602006003642D1/de active Active
- 2006-03-20 PL PL06727683T patent/PL1863474T3/pl unknown
- 2006-03-20 SI SI200630178T patent/SI1863474T1/sl unknown
- 2006-03-20 WO PCT/IB2006/050850 patent/WO2006100633A1/en active Application Filing
- 2006-03-20 JP JP2008502540A patent/JP5072825B2/ja not_active Expired - Fee Related
- 2006-03-20 CN CN2006800092312A patent/CN101146529B/zh not_active Expired - Fee Related
- 2006-03-20 US US11/909,436 patent/US7605269B2/en not_active Expired - Fee Related
- 2006-03-20 BR BRPI0609668-9A patent/BRPI0609668A2/pt not_active IP Right Cessation
- 2006-03-20 EP EP06727683A patent/EP1863474B1/en active Active
- 2006-03-20 ES ES06727683T patent/ES2316062T3/es active Active
- 2006-03-20 PT PT06727683T patent/PT1863474E/pt unknown
- 2006-03-22 AR ARP060101135A patent/AR055751A1/es not_active Application Discontinuation
- 2006-03-22 TW TW095109955A patent/TW200700406A/zh unknown
2007
- 2007-09-20 IL IL186150A patent/IL186150A0/en unknown
- 2007-10-17 NO NO20075298A patent/NO20075298L/no not_active Application Discontinuation
- 2007-10-22 ZA ZA200709087A patent/ZA200709087B/xx unknown
2009
- 2009-02-05 CY CY20091100133T patent/CY1108750T1/el unknown

Also Published As

Publication number	Publication date
JP2008534491A (ja)	2008-08-28
NZ562561A (en)	2010-11-26
IL186150A0 (en)	2008-01-20
WO2006100633A1 (en)	2006-09-28
US20080318955A1 (en)	2008-12-25
ZA200709087B (en)	2008-09-25
RU2007138869A (ru)	2009-04-27
KR20070116645A (ko)	2007-12-10
DE602006003642D1 (en)	2008-12-24
ATE413874T1 (de)	2008-11-15
US7605269B2 (en)	2009-10-20
EP1863474B1 (en)	2008-11-12
CA2602475C (en)	2014-11-04
ES2316062T3 (es)	2009-04-01
PT1863474E (pt)	2009-01-20
SI1863474T1 (sl)	2009-04-30
AU2006226020A1 (en)	2006-09-28
CA2602475A1 (en)	2006-09-28
BRPI0609668A2 (pt)	2011-10-18
DK1863474T3 (da)	2009-02-09
EP1863474A1 (en)	2007-12-12
AR055751A1 (es)	2007-09-05
CN101146529A (zh)	2008-03-19
PL1863474T3 (pl)	2009-04-30
RU2404178C2 (ru)	2010-11-20
CY1108750T1 (el)	2014-04-09
CN101146529B (zh)	2012-08-29
TW200700406A (en)	2007-01-01
JP5072825B2 (ja)	2012-11-14
NO20075298L (no)	2007-12-20

Publication	Publication Date	Title
MX2007011672A (es)	2007-11-15	Nuevos derivados de tiofeno como agonistas del receptor de esfingosina-1-fosfato-1.
TWI402262B (zh)	2013-07-21	新穎噻吩衍生物
KR101382710B1 (ko)	2014-04-08	신규한 티오펜 유도체
MX2007011669A (es)	2007-11-15	Nuevos derivados de tiofeno como agonistas del receptor de esfingosina-1-fosfato-1.
NZ576059A (en)	2012-03-30	Pyridin-3-yl derivatives as immunomodulating agents
MX2007016505A (es)	2008-03-07	Nuevos derivados de tiofeno.
AU2007209051A1 (en)	2007-08-02	Novel pyridine derivatives
CA2661102A1 (en)	2008-03-13	Thiophene derivatives as s1p1/edg1 receptor agonists
JP2009516735A (ja)	2009-04-23	新規チオフェン誘導体
HK1135976B (en)	2013-02-22	Pyridin-3-yl derivatives as immunomodulating agents
MX2008008838A (en)	2008-09-26	Novel thiophene derivatives as s1p1/edg1 receptor agonists
HK1133654A1 (en)	2010-04-01	Pyridin-4-yl derivatives as immunomodulating agents

Legal Events

Date	Code	Title	Description
2009-01-16	FG	Grant or registration